2m 2m 2m 2m 2m 2m 2m
ALAUNOS (TCRT)
NASDAQ
$1.93+$0.05 (+2.66%)
Price as of Jul 31, 2026 4:12 PM EDT- $4.6MMarket Cap
- -31.39%1-Year Change
- BiotechnologyIndustry
ALAUNOS (TCRT)
$1.93+$0.05 (+2.66%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 55
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$1.83
$1.92
$1.88
1-Year Range
$1.77
$4.36
$1.88
Latest Close$1.88
Change
$0.00 (0.00%)
Volume9,610
Market Cap$4.6M
Shares Outstanding2.4M
P/E (TTM)-0.93
Diluted EPS (TTM)-$2.02
Enterprise Value$4.2M
Information as of 07/31/2026
Company Profile
ALAUNOS THERAPEUTICS INC
https://www.alaunos.com$4.6M
Market Cap
-$4.1M
Net Income
Sector: Healthcare
Industry: Biotechnology
501 E. Las Olas Blvd., Fort Lauderdale, FL, United States, 33301
346 355 4099Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
Key Executives
- Holger Weis
- Ferdinand Groenewald
Current Ownership Distribution
- Institutions572.0M (78.43%)
- Mutual Funds152.3M (20.89%)
- Insiders5.0M (0.68%)
- Other0 (0.00%)